SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary arterial disease in May 2020. The US FDA has awarded the SELUTION SLR with four breakthrough designations for coronaries, peripheral vascular and AV Fistula indications.